Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CALIBRATE: a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Next Previous
Trial Profile

CALIBRATE: a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encaleret (Primary) ; Alfacalcidol; Calcitriol; Calcium supplements; Falecalcitriol
  • Indications Hypocalcaemia; Hypoparathyroidism
  • Focus Registrational; Therapeutic Use
  • Acronyms CALIBRATE
  • Sponsors BridgeBio Pharma; Calcilytix therapeutics

Most Recent Events

  • 13 Mar 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Aug 2025.
  • 13 Jan 2025 According to a Bridge Bioresearch media release, the trial is fully enrolled with 70 patients. The Company expects Last Patient - Last Visit and topline readout in second half 2025.
  • 13 Jan 2025 Status changed from recruiting to active, no longer recruiting, according to a Bridge Bioresearch media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top